News analysis

Capitalising on China's upcoming biotech boom

As early opportunities beckon, note risks like high failure rates and long gestation periods

Ageing societies are now translating into higher national healthcare bills the world over.

In Asia, medical cost inflation is further compounded by rapidly rising incidences of non-communicable diseases (NCDs), including hypertension and cancer, in part from the region's swift urbanisation rates.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*

*Terms and conditions apply.

A version of this article appeared in the print edition of The Straits Times on August 06, 2018, with the headline 'Capitalising on China's upcoming biotech boom'. Subscribe